Seeking Alpha

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...
ascopubs.org

Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response.

Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger. Background: To assess therapeutic response and treatment-related morbidity in patients treated with ...
Morningstar

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY ...

Highest reported pathologic complete response rate seen in a phase 3 registrational trial for HER2 positive early breast cancer with favorable safety profile versus standard treatment DESTINY-Breast11 ...